Published in FEMS Microbiol Lett on July 01, 1992
Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol (1995) 7.32
Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol (1993) 3.85
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
A method for producing specific antisera with small doses of immunogen. J Clin Endocrinol Metab (1971) 4.38
A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 4.30
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med (2001) 4.08
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol (1985) 2.97
Lipid on capsular polysaccharides of gram-negative bacteria. J Biol Chem (1981) 2.91
Frequency of E. coli K antigens in urinary-tract infections in children. Lancet (1977) 2.89
Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med (1979) 2.89
Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet (1971) 2.84
Use of antiserum agar for detection of Haemophilus influenzae type b in the pharynx. Pediatr Res (1975) 2.74
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry (1978) 2.65
Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2.59
The isolation and biologic activities of purified secretory IgA and IgG anti-Salmonella typhimurium "O" antibodies from rabbit intestinal fluid and colostrum. J Immunol (1971) 2.54
Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun (1972) 2.47
Serogroup identification of Neisseria meningitidis: comparison of an antiserum agar method with bacterial slide agglutination. J Clin Microbiol (1978) 2.44
Pathogenesis of neonatal Escherichia coli meningitis: induction of bacteremia and meningitis in infant rats fed E. coli K1. Infect Immun (1977) 2.39
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg (2000) 2.29
Differential complement resistance mediates virulence of Haemophilus influenzae type b. Infect Immun (1982) 2.23
Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis (1984) 2.17
Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med (1975) 2.16
Gamma-A-immunoglobulin from rabbit colostrum. J Immunol (1966) 2.16
Clinical, bacteriological, and immunological characterisation of ampicillin-resistant Haemophilus influenzae type B. Lancet (1974) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 2.10
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis (2000) 2.04
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis (1977) 1.84
Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun (1986) 1.79
A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med (1995) 1.78
Use of antiserum agar plates for serogrouping of meningococci. J Clin Pathol (1977) 1.74
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun (1993) 1.70
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun (1990) 1.69
Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides. Infect Immun (1979) 1.61
Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine (1996) 1.59
Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med (1987) 1.56
Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bull World Health Organ (1978) 1.52
Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply. Vaccine (1998) 1.51
Polyribitol-phosphate: an antigen of four gram-positive bacteria cross-reactive with the capsular polysaccharide of haemophilus influenzae type B. J Immunol (1974) 1.49
Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun (1976) 1.49
Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun (1983) 1.46
Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate. J Pediatr (1989) 1.46
Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect Immun (1992) 1.45
Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun (1991) 1.44
An outbreak of Hemophilus influenzae type b meningitis in an enclosed hospital population. J Pediatr (1976) 1.44
The infant rat as a model of bacterial meningitis. J Infect Dis (1977) 1.44
Age-related susceptibility to Haemophilus influenzae type b disease in rabbits. Infect Immun (1971) 1.43
Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun (1990) 1.43
Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun (1989) 1.42
Quantitative studies of the immunoglobulin sequence in the response of the rabbit to a somatic antigen. J Exp Med (1966) 1.40
Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun (1991) 1.39
Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Clin Infect Dis (1999) 1.39
Structural studies on the sialic acid polysaccharide antigen of Escherichia coli strain Bos-12. Biochemistry (1977) 1.38
Characterization of the Salmonella paratyphi C Vi polysaccharide. Infect Immun (1989) 1.37
Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun (1999) 1.36
Immunity to Hemophilus influenzae type b. I. The isolation, and some physicochemical, serologic and biologic properties of the capsular polysaccharide of Hemophilus influenzae type b. J Immunol (1971) 1.36
Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J Infect Dis (1979) 1.35
Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis (1986) 1.35
Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun (1973) 1.34
Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun (1984) 1.34
Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci U S A (1999) 1.34
Characterization of the cross-reaction between type 19F(19) and 19A(57) pneumococcal capsular polysaccharides: compositional analysis and immunological relation determined with rabbit typing antisera. Infect Immun (1978) 1.31
Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun (1986) 1.30
Heteroimmunization to the capsular polysaccharide of Haemophilus influenzae type b induced by enteric cross-reacting bacteria. Infect Immun (1975) 1.30
Soluble antigen-antibody complexes as intermediates in the purification of antibodies in 8 molar urea. Arch Biochem Biophys (1966) 1.30
Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect Immun (1998) 1.26
Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun (1994) 1.25
On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O:1, serotypes Ogawa and Inaba. J Biol Chem (1998) 1.25
Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun (1992) 1.23
Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci U S A (1991) 1.22
Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo. Infect Immun (2001) 1.21
Need for agreement on a single pneumococcal vaccine formulation. Lancet (1980) 1.21
Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect Immun (1990) 1.20
Host factors and antibody response Haemophilus influenza type b meningitis and epiglottitis. J Infect Dis (1976) 1.20
Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect Immun (1994) 1.18
Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J Exp Med (1985) 1.18
Neonatal meningitis due of Escherichia coli K1. J Infect Dis (1977) 1.18
Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect Immun (1996) 1.17
The attack rate, age incidence, racial distribution, and case fatality rate of Hemophilus influenzae type b meningitis in Mecklenbury County, North Carolina. J Pediatr (1972) 1.16
Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J Allergy Clin Immunol (1975) 1.16
Pneumocystis carinii pneumonitis. A review. Pediatr Res (1967) 1.15
Induction of Haemophilus influenzae type b capsular antibody in neonatal rabbits by gastrointestinal colonization with cross-reacting Escherichia coli. Infect Immun (1973) 1.14
Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr (1988) 1.14
Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect Immun (1988) 1.12
Hydrolytic stability of pneumococcal group 6 (type 6A and 6B) capsular polysaccharides. Infect Immun (1982) 1.10
Urinary-tract escherichia coli with cross-reactive antigens to encapsulated pyogenic bacteria. Lancet (1972) 1.09